» Articles » PMID: 23665268

Insight into the Binding Mode and the Structural Features of the Pyrimidine Derivatives As Human A2A Adenosine Receptor Antagonists

Overview
Journal Biosystems
Specialty Biology
Date 2013 May 14
PMID 23665268
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The interaction of 278 monocyclic and bicyclic pyrimidine derivatives with human A2A adenosine receptor (AR) was investigated by employing molecular dynamics, thermodynamic analysis and three-dimensional quantitative structure-activity relationship (3D-QSAR) approaches. The binding analysis reveals that the pyrimidine derivatives are anchored in TM2, 3, 5, 6 and 7 of A2A AR by the aromatic stacking and hydrogen bonding interactions. The key residues involving Phe168, Glu169, and Asn253 stabilize the monocyclic and bicyclic cores of inhibitors. The thermodynamic analysis by molecular mechanics/Poisson Boltzmann surface area (MM-PBSA) approach also confirms the reasonableness of the binding modes. In addition, the ligand-/receptor-based comparative molecular similarity indices analysis (CoMSIA) models of high statistical significance were generated and the resulting contour maps correlate well with the structural features of the antagonists essential for high A2A AR affinity. A minor/bulky group with negative charge at C2/C6 of pyrimidine ring respectively enhances the activity for all these pyrimidine derivatives. Particularly, the higher electron density of the ring in the bicyclic derivatives, the more potent the antagonists. The obatined results might be helpful in rational design of novel candidate of A2A adenosine receptor antagonist for treatment of Parkinson's disease.

Citing Articles

Exploration of chalcones and related heterocycle compounds as ligands of adenosine receptors: therapeutics development.

Matthee C, TerreBlanche G, Legoabe L, Janse van Rensburg H Mol Divers. 2021; 26(3):1779-1821.

PMID: 34176057 DOI: 10.1007/s11030-021-10257-9.


In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson's Disease.

Lemos A, Melo R, Preto A, Almeida J, Moreira I, Cordeiro M Curr Neuropharmacol. 2018; 16(6):786-848.

PMID: 29521236 PMC: 6080095. DOI: 10.2174/1570159X16666180308161642.


Recent Developments and Applications of the MMPBSA Method.

Wang C, Greene D, Xiao L, Qi R, Luo R Front Mol Biosci. 2018; 4:87.

PMID: 29367919 PMC: 5768160. DOI: 10.3389/fmolb.2017.00087.


Computer-aided Drug Design Applied to Parkinson Targets.

Ishiki H, Barbosa Filho J, da Silva M, Scotti M, Scotti L Curr Neuropharmacol. 2017; 16(6):865-880.

PMID: 29189169 PMC: 6080092. DOI: 10.2174/1570159X15666171128145423.


TCMSP: a database of systems pharmacology for drug discovery from herbal medicines.

Ru J, Li P, Wang J, Zhou W, Li B, Huang C J Cheminform. 2014; 6:13.

PMID: 24735618 PMC: 4001360. DOI: 10.1186/1758-2946-6-13.